Pfizer, Inc. (PFE)
PFE moved a median of -0.04% 30 minutes after news, and -0.07% by the close. How PFE actually reacts to news — the realized, point-in-time move the market made, measured across 721 labeled events over the last three years with zero look-ahead.
PFE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 45% | 719 |
| 30-min | -0.04% | 46% | 719 |
| 60-min | -0.02% | 47% | 719 |
| to close | -0.07% | 44% | 715 |
| Middle 50% of PFE reactions | -0.38% to +0.26% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 721 |
Half of all Pfizer, Inc. news events land between -0.38% and +0.26% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PFE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 28 | -0.09% | 50% | -0.55% |
| Analyst downgrades | 18 | -0.09% | 39% | -0.60% |
| Coverage initiations | 27 | -0.02% | 41% | 0.00% |
| Rating reiterations | 122 | 0.00% | 47% | -0.09% |
| Price-target raises | 15 | -0.02% | 27% | 0.00% |
| Price-target cuts | 24 | +0.15% | 67% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how PFE ranks against every other measured name →
That’s how PFE usually reacts — get an email when it moves on news →Email me when PFE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PFE's baseline. Nothing else.
Recent PFE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 | Press release | Business Wire | +0.85% | +1.96% | |
| Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer | Press release | Business Wire | +0.11% | -0.20% | |
| Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 | Press release | PR Newswire | +0.40% | +1.34% | |
| Pfizer Declares Fourth-Quarter 2026 Dividend | Press release | Business Wire | +0.00% | -0.07% | |
| Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo | Press release | Business Wire | +0.18% | +0.31% | |
| Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study | Press release | Business Wire | +0.35% | -1.09% | |
| Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO | Press release | Business Wire | -0.12% | +0.35% | |
| Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts | Press release | Business Wire | +0.14% | +1.05% | |
| Health Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine | Press release | Canada Newswire | +0.02% | +0.04% | |
| Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference | Press release | Business Wire | -0.02% | +0.79% | |
| Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference | Press release | Business Wire | +0.00% | -1.12% | |
| Form N-PX PFIZER INC For: Jun 30 | SEC filing · Form N-PX | SEC EDGAR | +0.02% | -1.11% | |
| Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine | Press release | Business Wire | -0.27% | -0.14% | |
| Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency | Press release | Business Wire | -0.26% | +0.83% | |
| Form 13F-HR PFIZER INC For: Jun 30 | SEC filing · Form 13F-HR | SEC EDGAR | -0.26% | +0.83% | |
| Form 10-Q PFIZER INC For: Jun 28 | SEC filing · Form 10-Q | SEC EDGAR | +0.73% | +2.67% | |
| Form 8-K PFIZER INC For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | +2.67% | |
| Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance | Press release | Business Wire | +0.73% | +2.67% | |
| Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo | Press release | Business Wire | -0.38% | +0.36% | |
| European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union | Press release | Business Wire | -0.38% | +0.36% | |
| Pfizer's PREVNAR 20™ Selected for Québec's Publicly Funded Pediatric Pneumococcal Immunization Program | Press release | Canada Newswire | -0.67% | -0.79% | |
| FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer | Press release | Business Wire | +0.42% | +0.56% | |
| U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility | Press release | Business Wire | +0.04% | -0.27% | |
| Perioperative Option Approved in Canada for Patients with Muscle-Invasive Bladder Cancer Unable to Receive Cisplatin-Based Therapy | Press release | Canada Newswire | +0.21% | +0.29% | |
| FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance | Press release | Business Wire | +0.08% | +0.19% | |
| Pfizer Declares Third-Quarter 2026 Dividend | Press release | Business Wire | -0.25% | -0.52% | |
| Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts | Press release | Business Wire | +0.14% | -0.54% | |
| Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer | Press release | Business Wire | +0.00% | -1.12% | |
| Form 8-K PFIZER INC For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | -1.14% | |
| Pfizer Announces Chief Financial Officer Transition | Press release | Business Wire | -0.28% | -1.14% | |
| Form 11-K PFIZER INC For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | +0.21% | +0.19% | |
| U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need | Press release | Business Wire | -0.15% | -1.73% | |
| Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide | Press release | Business Wire | -0.15% | -1.73% | |
| Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference | Press release | Business Wire | -0.12% | -0.41% | |
| Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer | Press release | Business Wire | -0.52% | -0.77% | |
| TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer | Press release | Business Wire | -0.52% | -0.77% | |
| Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer | Press release | Business Wire | -0.36% | -0.08% | |
| Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines | Press release | PR Newswire | -0.36% | -0.08% | |
| Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines | Press release | Business Wire | -0.36% | -0.08% | |
| Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference | Press release | Business Wire | -0.15% | -0.55% | |
| Pfizer's BRAFTOVI® Becomes First Pfizer Therapy to Receive Priority Access Under Ontario's FAST Program, Accelerating Treatment for Canadians with Metastatic Colorectal Cancer | Press release | Canada Newswire | -0.06% | +0.31% | |
| Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results | Press release | Business Wire | -0.14% | -0.27% | |
| European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors | Press release | Business Wire | +0.39% | +0.62% | |
| Form 13F-HR PFIZER INC For: Mar 31 | SEC filing · Form 13F-HR | SEC EDGAR | +0.39% | +0.62% | |
| Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates | Press release | GlobeNewswire | +0.10% | +0.04% | |
| Form 10-Q PFIZER INC For: Mar 29 | SEC filing · Form 10-Q | SEC EDGAR | -0.74% | -0.64% | |
| Form 8-K PFIZER INC For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | -0.64% | |
| Form S-8 PFIZER INC | SEC filing · Form S-8 | SEC EDGAR | -0.53% | -0.19% | |
| Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance | Press release | Business Wire | -0.74% | -0.64% | |
| Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma | Press release | Business Wire | +0.82% | -0.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PFE section they belong to.
Where else PFE is measured.
PFE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| RETROPHIN INC (RTRX) | 723 | +0.06% | 52% |
| IsoRay, Inc. (DE) (ISR) | 722 | -0.01% | 45% |
| ESSA Pharma Inc. (EPIX) | 718 | 0.00% | 38% |
| Tricida, Inc. (TCDA) | 715 | +0.06% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Pfizer, Inc.'s median reaction calculated?
Every labeled PFE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 721 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of PFE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PFE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.